BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23564048)

  • 1. Pharmacological agents with inherent anti-autophagic activity improve the cytotoxicity of imatinib.
    Crowley LC; O'Donovan TR; Nyhan MJ; McKenna SL
    Oncol Rep; 2013 Jun; 29(6):2261-8. PubMed ID: 23564048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
    Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
    Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib.
    Mancini M; Leo E; Campi V; Castagnetti F; Zazzeroni L; Gugliotta G; Santucci MA; Martinelli G
    Cell Signal; 2014 Aug; 26(8):1690-7. PubMed ID: 24747551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
    Crowley LC; Elzinga BM; O'Sullivan GC; McKenna SL
    Am J Hematol; 2011 Jan; 86(1):38-47. PubMed ID: 21132731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methyl-β-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling.
    Yan J; Li QF; Wang LS; Wang H; Xiao FJ; Yang YF; Wu CT
    Anticancer Drugs; 2012 Jan; 23(1):22-31. PubMed ID: 21857502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
    Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
    Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.
    Shi R; Lin J; Gong Y; Yan T; Shi F; Yang X; Liu X; Naren D
    Anticancer Drugs; 2015 Oct; 26(9):913-22. PubMed ID: 26186064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
    Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
    Gómez-Casares MT; García-Alegria E; López-Jorge CE; Ferrándiz N; Blanco R; Alvarez S; Vaqué JP; Bretones G; Caraballo JM; Sánchez-Bailón P; Delgado MD; Martín-Perez J; Cigudosa JC; León J
    Oncogene; 2013 Apr; 32(17):2239-46. PubMed ID: 22710719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anticancer drug imatinib induces cellular autophagy.
    Ertmer A; Huber V; Gilch S; Yoshimori T; Erfle V; Duyster J; Elsässer HP; Schätzl HM
    Leukemia; 2007 May; 21(5):936-42. PubMed ID: 17330103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure.
    Ovcharenko A; Granot G; Rokah OH; Park J; Shpilberg O; Raanani P
    Leuk Res; 2013 Dec; 37(12):1729-36. PubMed ID: 24176282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells.
    Shingu T; Fujiwara K; Bögler O; Akiyama Y; Moritake K; Shinojima N; Tamada Y; Yokoyama T; Kondo S
    Int J Cancer; 2009 Mar; 124(5):1060-71. PubMed ID: 19048625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and preclinical evaluation of NRC-AN-019.
    Amala K; Bhujanga Rao AK; Gorantla B; Gondi CS; Rao JS
    Int J Oncol; 2013 Jan; 42(1):168-78. PubMed ID: 23151973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.